alexa [Treatment of bone metastasis with anti-RANKL antibody].
Oncology

Oncology

Journal of Cancer Science & Therapy

Author(s): Chayahara N, Minami H

Abstract Share this page

Abstract Bone metastases are a frequent complication of solid cancers including breast, prostate, and lung cancers. Control of this complication is clinically important, because they cause skeletal-related events including pathological fractures that impair quality of life (QOL) or shorten survival of patient with bone metastasis. Recently, denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-κB ligand was developed as a therapeutic agent for bone metastases. In three phase III trials, denosumab is superior to zoledronic acid, a potent bisphosphonate used as the standard therapy for bone metastases, for patients with prostate or breast cancers and is noninferior for patients with other solid tumors in terms of the median time to first on-study skeletal-related event. It will be an effective new treatment option for patients with bone metastases. This article was published in Clin Calcium and referenced in Journal of Cancer Science & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords